Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gentamicin bone cement, developed by Sanskruti Pharma, is a drug-device combination used in orthopedic surgery to secure prosthetic implants and provide local antibiotic prophylaxis. It consists of an acrylic polymer, polymethylmethacrylate (PMMA), which acts as a structural grout, and the aminoglycoside antibiotic gentamicin. Upon implantation, the cement hardens and slowly elutes gentamicin into the surrounding tissue and bone. This local delivery achieves high bactericidal concentrations at the surgical site, effectively targeting common pathogens like Staphylococcus aureus while minimizing systemic exposure and associated side effects such as nephrotoxicity. Gentamicin's mechanism involves binding to the 30S ribosomal subunit of bacteria, leading to misreading of mRNA and inhibition of protein synthesis, which ultimately results in bacterial cell death.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gentamicin bone cement.